Ausbil Investment Management Ltd Purchases 1,504 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Ausbil Investment Management Ltd increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 27.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,974 shares of the company’s stock after acquiring an additional 1,504 shares during the quarter. Medpace comprises 1.4% of Ausbil Investment Management Ltd’s holdings, making the stock its 28th biggest position. Ausbil Investment Management Ltd’s holdings in Medpace were worth $2,776,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the company. Miller Howard Investments Inc. NY increased its stake in Medpace by 1.3% during the 4th quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company’s stock valued at $943,000 after purchasing an additional 39 shares in the last quarter. Coldstream Capital Management Inc. increased its stake in Medpace by 5.0% during the 4th quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock valued at $292,000 after purchasing an additional 45 shares in the last quarter. GAMMA Investing LLC increased its stake in Medpace by 43.3% during the 1st quarter. GAMMA Investing LLC now owns 149 shares of the company’s stock valued at $60,000 after purchasing an additional 45 shares in the last quarter. Campbell Newman Asset Management Inc. increased its stake in Medpace by 0.4% during the 4th quarter. Campbell Newman Asset Management Inc. now owns 11,095 shares of the company’s stock valued at $3,401,000 after purchasing an additional 46 shares in the last quarter. Finally, Treasurer of the State of North Carolina increased its stake in Medpace by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 10,230 shares of the company’s stock valued at $2,477,000 after purchasing an additional 50 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 1.1 %

MEDP traded up $4.78 during midday trading on Friday, hitting $429.12. 46,147 shares of the company traded hands, compared to its average volume of 228,421. The company has a market capitalization of $13.29 billion, a price-to-earnings ratio of 43.26, a PEG ratio of 2.01 and a beta of 1.39. Medpace Holdings, Inc. has a 52-week low of $227.21 and a 52-week high of $435.98. The business has a 50 day simple moving average of $396.33 and a two-hundred day simple moving average of $366.08.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. The firm had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company’s revenue for the quarter was up 17.7% on a year-over-year basis. During the same period last year, the firm posted $2.27 earnings per share. Equities research analysts anticipate that Medpace Holdings, Inc. will post 11.29 earnings per share for the current year.

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 5,695 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $395.49, for a total transaction of $2,252,315.55. Following the completion of the sale, the chief executive officer now directly owns 654,656 shares in the company, valued at $258,909,901.44. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO August J. Troendle sold 5,695 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $395.49, for a total transaction of $2,252,315.55. Following the completion of the sale, the chief executive officer now directly owns 654,656 shares in the company, valued at $258,909,901.44. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 3,987 shares of Medpace stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $395.22, for a total transaction of $1,575,742.14. Following the sale, the chief executive officer now owns 660,351 shares of the company’s stock, valued at $260,983,922.22. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,621 shares of company stock valued at $11,816,852. Corporate insiders own 20.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on MEDP shares. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and increased their price objective for the stock from $340.00 to $450.00 in a research note on Tuesday, April 23rd. Robert W. Baird increased their price objective on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Mizuho started coverage on shares of Medpace in a research note on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price objective on the stock. Guggenheim increased their price objective on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, TD Cowen started coverage on shares of Medpace in a research note on Wednesday, May 29th. They issued a “buy” rating and a $452.00 price objective on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $443.14.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.